Dezacor

Quick links to important sections

Dezacor

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dezacor

Property Description
Active Ingredient Deflazacort
Primary Form Tablet, Oral Suspension
Pharmacological Class Glucocorticoid (Corticosteroid)
General Purpose Anti-inflammatory and Immunosuppressive
Origin Synthetic derivative of Prednisolone

Dezacor: Definition and Pharmacological Classification

Dezacor is a pharmaceutical product containing the active ingredient Deflazacort, which is classified as a potent glucocorticoid within the broader corticosteroid pharmacological class. This medicine is a synthetic steroid drug derived from prednisolone, intended for systemic use. Deflazacort's core function as a Corticosteroid Hormone Receptor Agonist is widely supported by pharmacological studies, confirming its role in modulating gene expression related to inflammation.

Composition and Available Forms

The unique composition of Dezacor is defined by Deflazacort being administered as an inactive prodrug that requires immediate conversion by the body into its active and potent metabolite, 21-desacetyldeflazacort. This necessary conversion is a key differentiating feature in its profile. The medicine is administered via the oral route and is available in two distinct dosage forms: a solid preparation as a tablet and a liquid oral suspension. The availability of both forms assists patients who may need flexibility in administration.

General Purpose: Anti-inflammatory and Immunomodulation

Dezacor's primary therapeutic purpose is to provide powerful anti-inflammatory and immunosuppressive effects by fundamentally modifying the activity of the body's immune system. Its mechanism is clinically recognized for suppressing the chronic inflammatory processes that drive many systemic conditions. For example, the drug's action helps reduce widespread internal swelling and mitigate undesirable immune responses, making it suitable for patient groups needing significant immunomodulation.

Regulatory References

  1. Glucocorticoid
  2. corticosteroid
  3. PubChem
  4. synthetic steroid drug
  5. systemic use
  6. Corticosteroid Hormone Receptor Agonist
  7. 21-desacetyldeflazacort
  8. MedlinePlus
  9. anti-inflammatory
  10. immunosuppressive

What side effects are possible with Dezacor?

Possible Side Effects and Safety Information

Dezacor (Deflazacort) is a systemic glucocorticoid, and its official safety profile reflects known effects of this class of medicine on the body's systems, as documented in regulatory sources.


Frequency-Classified Adverse Reactions

Regulatory documents classify several adverse reactions based on their observed frequency. Reactions listed as very common (occurring in ge 10% of patients in trials) often include metabolic and physical changes. These frequently reported effects include Cushingoid appearance (facial puffiness), increased appetite, weight increased, central obesity, and hirsutism. Common infectious effects such as upper respiratory tract infection and cough are also noted.


Systemic Safety Considerations

The medicine is associated with potential effects across multiple organ classes. Notable safety concerns detailed in official warnings involve:

  • Endocrine and Metabolic Function: Risk of Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and hyperglycemia. Abrupt discontinuation may lead to Acute Adrenal Insufficiency.
  • Infections and Immunosuppression: Increased risk of developing or exacerbating serious infections (viral, bacterial, fungal) due to the drug's immunosuppressive action.
  • Musculoskeletal and Ophthalmic Effects: Long-term use is specifically associated with the risk of decreased bone mineral density (osteoporosis), cataracts, and glaucoma.

Population and Contextual Safety Notes

Official labeling contains specific notes on high-level constraints. The medication may slow growth and development in children with long-term use. Additionally, the label specifies a restriction on the co-administration of live or live attenuated vaccines during immunosuppressive therapy. Dezacor is generally contraindicated in patients with a known hypersensitivity to the product or in those with active systemic fungal infections.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation indicates that cases of acute Dezacor (Deflazacort) overdose are generally not reported. The primary overdose concern is linked to prolonged exposure to high doses, which may result in a state of functional overdose with documented systemic manifestations.

Documented Overdose Manifestations

High-level exposure over time is associated with clinical signs consistent with Cushing’s syndrome and the physiological finding of Hypothalamic-pituitary-adrenal (HPA) axis suppression. Other documented clinical findings include Hyperglycemia and Hypertension. A severe, life-threatening outcome associated with this chronic functional overdose is Acute Adrenal Insufficiency, which may occur upon abrupt withdrawal following prolonged HPA axis suppression. Patients with hepatic impairment may have increased Deflazacort blood levels, requiring dose adjustment to avoid excessive exposure.

Emergency Actions and Management

If an overdose is suspected, contact the poison control helpline. Immediate emergency medical attention is required when severe clinical signs occur. According to government guidance, individuals should Immediately call emergency services if experiencing symptoms such as collapse, seizure, or trouble breathing.

In the event of an overdose, no specific antidote is known. Management is based entirely on providing symptomatic measures are advised and supportive treatment is advised, as stipulated by regulatory authorities. Monitoring for signs of HPA axis suppression is required.

Therapeutic Uses of Dezacor

What Dezacor Treats: Main Uses and Benefits

Dezacor (Deflazacort) is a glucocorticoid generally used for its anti-inflammatory and immunosuppressive properties across several complex disease domains. Its core benefit is linked to managing symptoms associated with systemic imbalance and inflammation.

This medication is commonly applied in the long-term management of Duchenne Muscular Dystrophy (DMD) in patients aged 2 years and older. The primary therapeutic benefit may assist with managing symptoms related to progressive muscle weakness and functional decline. It may assist with managing symptoms of increased neurological or muscular activity and assists with maintaining functional stability, contributing to easing the overall symptom load.

Dezacor's therapeutic action is generally applied in conditions characterized by periods of heightened symptoms and requiring additional symptomatic support. These conditions include major Systemic Autoimmune and Rheumatic Disorders such as Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis, as well as other conditions where symptoms are linked to organ-specific functional stress caused by inflammation, such as certain forms of chronic asthma and Nephrotic Syndrome.

“This therapeutic approach is relevant in contexts involving heightened systemic burden where long-term immune modulation is required.”

For these conditions, Dezacor is used for managing symptoms related to widespread internal inflammation, joint swelling, and pain linked to inflammatory or irritative states. Its use supports the patient during difficult episodes by easing distress and helps improve day-to-day comfort during symptomatic periods.


Quick Fact: Relief for Systemic Inflammation

Dezacor is relevant for easing challenging symptoms in conditions marked by chronic, internal swelling and symptoms related to heightened physiological activity, assisting with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus overview on Deflazacort

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Dezacor — Official Regulatory Information

The eligibility profile for Dezacor (Deflazacort) is defined by strict regulatory criteria based on age, physiological status, and pre-existing conditions.


Eligibility Scope

Category Eligibility Rule
Allowed Age Group Patients 2 years of age and older for its primary labeled use.
Absolute Contraindications Patients with known hypersensitivity to the medicine or its ingredients, and those with Systemic Fungal Infections. Use is also prohibited if receiving live or live attenuated vaccines.
Use Not Established Children younger than 2 years of age, as safety and effectiveness have not been established. The oral suspension form is specifically restricted in this age group.
Conditional Restrictions Patients with Severe Hepatic Impairment (no established dosing recommendations). Use is not recommended in breastfeeding patients. Pregnancy requires a determination that potential benefit outweighs risk.
Special Caution Required for patients with pre-existing conditions such as Gastrointestinal Disorders (e.g., active peptic ulcers) or certain latent infections (e.g., Tuberculosis).

Eligibility Classification Summary

Regulatory documentation classifies Dezacor use as Contraindicated in certain populations and Not Established in children under two years. Eligibility is conditional upon the patient's age and the absence of specific health issues, such as severe liver dysfunction. This structure ensures adherence to population constraints defined by government health authorities.

What should I know about interactions with other medicines?

Dezacor (Deflazacort) is a substrate of the CYP3A4 enzyme, and its interaction profile is heavily influenced by medicines that affect this metabolic pathway. Co-administration with strong or moderate CYP3A4 inhibitors (such as ketoconazole, clarithromycin, or grapefruit juice) increases the body's exposure to the active metabolite, 21-desDFZ, which may increase the risk of side effects; this requires a dosage reduction of Dezacor.

Conversely, concurrent use with CYP3A4 inducers (such as phenytoin, carbamazepine, or rifampin) can decrease the active metabolite's concentration, which may reduce the medicine's effectiveness. Avoidance of strong inducers is recommended. Patients should also avoid consuming grapefruit or grapefruit juice due to its inhibitory effect on CYP3A4.

As a corticosteroid, Dezacor suppresses the immune system. Therefore, it is generally advised to avoid administration of live or live-attenuated vaccines during Dezacor therapy due to the risk of infection and the potential for a diminished immune response. Additionally, Dezacor can increase blood glucose levels, which may necessitate adjustments in the dosage of antidiabetic drugs to maintain blood sugar control. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may increase the risk of gastrointestinal irritation when taken with Dezacor. Dosage of Dezacor may also require adjustment in patients with altered thyroid function.

Mechanism of Action

Targeted Modulation of Key Receptor Systems

Dezacor works by selectively engaging specific receptor or enzyme systems within the body's communication pathways. By acting as a modulator, the drug adjusts the activity of these initial molecular targets, acting on dysregulated signaling patterns within targeted physiological pathways. This interaction results in a specific modulation of the biological target, which subsequently influences cellular responses.

Regulation of Downstream Signaling Cascades

The interaction at the receptor level initiates a change that dampens overactive molecular cascades. Dezacor's action interferes with the signal transduction sequence, limiting the amplification of the signal from the cell surface to intracellular components. This targeted pathway interference limits the downstream effects of excessive mediator activity, resulting in the modulation of physiological response dynamics within the affected system. The mechanism involves the adjustment of pathway activity within the targeted systems, and contributes to changes in physiological pathway activity that define the drug's effect profile.

Dosage and Administration Information

How to Use Dezacor

Dezacor (deflazacort) is administered via the oral route for systemic use, with the required regimen based strictly on official guidelines. The medicine is available as tablets (in multiple strengths) and as an oral suspension.


Official Administration Schedule

Dezacor is typically used for long-term management or short-term courses, and treatment is generally structured around a once-daily (qDay) dosing schedule.

Usage Parameter Regulatory Guideline
Standard Dosing Principle The primary official regimen is weight-based, calculated at approximately 0.9 mg per kilogram of body weight per day.
Timing Relative to Food The medicine can be taken with or without food.
Population Rule The weight-based dosing is indicated for patients aged 2 years and older.
Discontinuation Pattern If the medicine is taken for more than a few days, the dose must be gradually decreased (tapered) to stop treatment.

Preparation and Intake Instructions

Proper preparation is required for accurate delivery of the dose. Tablets may be swallowed whole, or they can be crushed and mixed with a small amount of applesauce; this mixture must be consumed immediately. The oral suspension must be shaken well before measuring the dose, and it may be mixed with three to four ounces of milk or juice for consumption, but must not be mixed with grapefruit juice. Doses should be calculated and rounded up to the nearest achievable tablet combination or the nearest tenth of a milliliter (0.1 mL) for the oral suspension. If a dose is missed, it should be taken as soon as possible on the same day, but subsequent doses should not be doubled.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dezacor

The research base for Dezacor (Deflazacort) consists of randomized controlled trials (RCTs), long-term observational studies, and systematic reviews that have examined its profile in several conditions. The evidence primarily focuses on measuring how symptoms and functional abilities evolved over defined time periods in the populations studied.


Evidence for Use in Duchenne Muscular Dystrophy (DMD)

Research for Dezacor in DMD primarily was studied for how it relates to functional measures, such as mobility and muscle strength, in children and adolescents. The core evidence stems from short-term randomized controlled trials where the medicine was evaluated in patients over periods ranging from a few weeks up to one year. Studies examined outcomes reflecting daily functioning or activity level, including the six-minute walk distance (6MWD) and timed tests of mobility.

In these trials, measurements of muscle strength and functional mobility were observed in the groups receiving Dezacor compared to groups receiving placebo. Observational studies, which follow large groups of patients over many years, reported an association with a later median age for the loss of ambulation (LoA) milestone compared to historical groups. Research also explored outcomes monitoring physiological strain or stress, with observational reports indicating patterns related to pulmonary function measurements over time.

Evidence for Systemic Autoimmune and Rheumatic Disorders

Research investigating Dezacor in contexts involving chronic systemic inflammation, such as Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA), is based on comparative trials and systematic reviews. Studies explored outcomes related to systemic or functional imbalance by measuring established disease activity indices. Some comparative trials reported similar patterns in measured disease activity indices over follow-up periods that were limited compared to other standard glucocorticoids.


What the Research Landscape Still Needs to Clarify

The current research landscape presents several areas where further investigation is needed. Long-term effects are not fully established by high-quality randomized trials; much of the long-term knowledge relies on observational studies where evidence quality varies. Comparative evidence is lacking from large-scale, head-to-head RCTs designed to directly evaluate the drug against all standard corticosteroid treatments over periods greater than one year. Furthermore, subgroup findings are uncertain for specific patient characteristics, and sample sizes were modest in many of the older trials for inflammatory disorders.

Frequently Asked Questions (FAQ)

Common questions about Dezacor (FAQ)


Q: What is the difference between Dezacor and prednisone?

A: Dezacor is a synthetic derivative of prednisone, which is a related steroid medicine. Official studies comparing the two treatments have noted differences in the side effect profile, such as observations of a lower incidence of weight gain and abnormal behavior in certain patient groups receiving Dezacor.


Q: How long after stopping Dezacor does it stay in the body?

A: The active form of the medicine is removed relatively quickly from the body. Official pharmacological information indicates its half-life—the time it takes for half the dose to be eliminated—is generally between 1.1 and 1.9 hours. The medicine is primarily removed from the body through the kidneys.


Q: What happens if I forget to take my Dezacor dose?

A: According to the official patient instructions, if a dose is missed, it can be taken as soon as it is remembered on the same day. Regulatory guidance indicates the missed dose is skipped if not remembered until the following day.


Q: Can Dezacor be taken during pregnancy?

A: The use of Dezacor during pregnancy requires careful consideration. Official labeling states that the medicine's use during pregnancy requires a determination that the potential benefit outweighs the potential risk to the fetus.


Q: Can Dezacor be taken while breastfeeding?

A: Systemic corticosteroids are known to be excreted into human milk. Regulatory information indicates that use while breastfeeding requires a careful assessment, as the anticipated benefit must be considered to outweigh the potential risk to the infant.


Q: Is there a generic version of Dezacor available?

A: Yes, the active ingredient in Dezacor, which is deflazacort, is available in an FDA-approved generic form. This generic product is available to patients as both tablets and an oral suspension.


Q: What are the long-term effects of taking Dezacor?

A: Official warnings and precautions indicate that long-term use is associated with potential effects across multiple systems. These effects include a risk of adrenal gland problems, a decrease in bone density (osteoporosis), and eye-related issues such as cataracts and glaucoma. Long-term use may also affect growth in children.


Q: What information should I provide my doctor before starting Dezacor?

A: Official labeling advises informing the doctor about a full medical history. This includes a history of infections (like chickenpox, measles, or tuberculosis), heart conditions, high blood pressure, diabetes, kidney or liver disease, and all current medications, including any recent or planned vaccines.


Q: Does Dezacor interact with common supplements like vitamins or herbal products?

A: The medicine has documented interactions with certain substances, such as Vitamin D3 (cholecalciferol) and specific foods like grapefruit. Patients are advised to inform their healthcare provider about all medications, supplements, vitamins, and herbal products they are using due to potential interaction risks.


Q: Are there any specific organs that Dezacor affects over time?

A: The medicine is a systemic corticosteroid, which means it can affect multiple organ systems. Official warnings cite potential effects on the endocrine (adrenal) system, the musculoskeletal system (bone density), and the eyes (cataracts and glaucoma).


Q: How quickly does Dezacor start to work, based on studies?

A: Studies have reported measurable effects on pain and swelling in some patients occurring within the first 6 to 12 hours following administration, demonstrating rapid anti-inflammatory properties.


Q: What should I do if I experience a stomach upset from Dezacor?

A: Official documentation mentions that an upset stomach is a commonly reported effect of this medicine. Official patient information has noted that taking the medicine after meals is often suggested to help lessen this effect.


Q: Is it possible to become dependent on Dezacor?

A: The medicine can cause suppression of the body's natural production of steroids, a condition known as HPA axis suppression. Due to this potential effect, regulatory information cautions against abrupt discontinuation, as stopping suddenly may result in serious side effects.


Q: Are there any restrictions on driving or operating machinery while on Dezacor?

A: Official safety information indicates that patients who experience side effects such as unusual tiredness, weakness, or dizziness should avoid driving or operating heavy machinery.


Q: Is a specific blood test required before starting Dezacor?

A: Official labeling advises that the patient's progress should be monitored at regular healthcare visits. This monitoring may involve blood or urine tests to check for unwanted effects, such as changes in blood sugar or electrolyte levels.


Q: Are there any known issues with taking Dezacor and alcohol?

A: Information from official product safety sources advises against the consumption of alcohol while taking this medicine. The regulatory advice regarding alcohol consumption is intended to reduce the risk of potential adverse effects.


Q: What are the most common serious side effects from Dezacor?

A: Official documentation classifies the most frequent adverse reactions as very common (ge 10% occurrence in studies), which include facial puffiness (Cushingoid appearance), increased appetite, and weight gain. Serious but less frequent warnings involve the risk of severe infections and adrenal insufficiency.


Q: Is Dezacor safe for people with kidney problems?

A: Patients with kidney impairment may not require a dose adjustment. However, official labeling advises caution and consultation for all patients with pre-existing fluid retention or renal dysfunction.


Q: What types of allergic reactions are reported with Dezacor?

A: Signs of a potential allergic reaction listed in safety information include hives, difficulty breathing, swelling of the face or throat, and severe skin reactions such as rash with blistering and peeling.


Q: Is it common to feel tired when starting Dezacor?

A: The official side effect profile includes reports of unusual tiredness or weakness. This should be monitored, as it may be a side effect itself or a sign of low adrenal gland function, which is a condition associated with the medicine.


Q: Is Dezacor used for treating muscle weakness?

A: The medicine is approved for treating Duchenne muscular dystrophy (DMD), a progressive disease characterized by muscle weakness. In this context, the medicine is intended to help maintain muscle strength in patients.

How should Dezacor be stored and disposed of?

How to Store and Dispose of Deflazacort

Deflazacort tablets and oral suspension must be stored at Controlled Room Temperature (CRT), defined as 20 C to 25 C (68 F to 77 F). The tablets require protection from moisture and light and should be kept in a tight, child-resistant container.


Storage and Stability Rules

Product Form Specific Requirement
Tablets Must be kept in a tight, light-resistant container.
Oral Suspension Discard any unused portion one month after opening the bottle.

Disposal and Safety

All forms must be stored out of the sight and reach of children. Disposal of unused or expired medication should utilize an official drug take-back program. If a program is unavailable, Deflazacort should be mixed with an unappealing substance, sealed in a bag, and thrown into the household trash. This medicine is not on the flush list for disposal via the toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dezacor found in:

A-Z Index: